Our data indicate that the rate of enhancement significantly decreases in the more advanced phases of MS. This is important when planning clinical trials, and suggests that mechanisms underlying lesion formation might be dissimilar in different MS patient groups.
IJ van den Elskamp, DL Knol, Hugo Vrenken, Giorgos B. Karas, A. Meijerman, Massimo Filippi, Ludwig Kappos, Franz Fazekas, K. Wagner, Christopher Pohl, Rupert Sandbrink, CH Polman, Bernard M.J. Uitdehaag, Frederik Barkhof
Discussion(0)
No comments yet. Be the first to comment.